CA2144327A1 - Transcutaneous in vivo activation of photosensitive agents in blood - Google Patents

Transcutaneous in vivo activation of photosensitive agents in blood

Info

Publication number
CA2144327A1
CA2144327A1 CA002144327A CA2144327A CA2144327A1 CA 2144327 A1 CA2144327 A1 CA 2144327A1 CA 002144327 A CA002144327 A CA 002144327A CA 2144327 A CA2144327 A CA 2144327A CA 2144327 A1 CA2144327 A1 CA 2144327A1
Authority
CA
Canada
Prior art keywords
target cells
cells
transcutaneous
blood
vivo activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002144327A
Other languages
French (fr)
Other versions
CA2144327C (en
Inventor
Anna M. Richter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novelion Therapeutics Inc
Original Assignee
Anna M. Richter
Quadra Logic Technologies, Inc.
Qlt Phototherapeutics Inc.
Qlt Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anna M. Richter, Quadra Logic Technologies, Inc., Qlt Phototherapeutics Inc., Qlt Inc. filed Critical Anna M. Richter
Publication of CA2144327A1 publication Critical patent/CA2144327A1/en
Application granted granted Critical
Publication of CA2144327C publication Critical patent/CA2144327C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A method destroys or impairs target cells that have selectively accumulated a photosensitizing agent. The target cells are in the bloodstream of an intact animal, which bloodstream and animal further contain non-target cells. Radiation is applied tran-scutaneously to at least a portion of the intact animal at an intensity effective to impair or destroy selectively the target cells and to leave non-target cells relatively unimpaired. Target cells include leukemia cells, virus-containing cells, parasite-containing cells, and microorganisms such as bacteria, parasites and free viruses.
CA002144327A 1992-09-21 1993-09-20 Transcutaneous in vivo activation of photosensitive agents in blood Expired - Fee Related CA2144327C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94811392A 1992-09-21 1992-09-21
US07/948,113 1992-09-21
PCT/CA1993/000382 WO1994006424A1 (en) 1992-09-21 1993-09-20 Transcutaneous in vivo activation of photosensitive agents in blood

Publications (2)

Publication Number Publication Date
CA2144327A1 true CA2144327A1 (en) 1994-03-31
CA2144327C CA2144327C (en) 2002-08-06

Family

ID=25487290

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002144327A Expired - Fee Related CA2144327C (en) 1992-09-21 1993-09-20 Transcutaneous in vivo activation of photosensitive agents in blood

Country Status (21)

Country Link
US (2) US5484803A (en)
EP (1) EP0660712B1 (en)
JP (2) JP3598306B2 (en)
AT (1) ATE201596T1 (en)
AU (1) AU681088B2 (en)
CA (1) CA2144327C (en)
DE (1) DE69330277T2 (en)
DK (1) DK0660712T3 (en)
ES (1) ES2160600T3 (en)
FI (1) FI951295A (en)
GR (1) GR3036479T3 (en)
HU (1) HU220251B (en)
IL (1) IL107035A (en)
NO (1) NO951066L (en)
NZ (1) NZ255302A (en)
PL (1) PL308116A1 (en)
PT (1) PT660712E (en)
SK (1) SK35295A3 (en)
TW (1) TW241204B (en)
WO (1) WO1994006424A1 (en)
ZA (1) ZA936968B (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955490A (en) * 1989-07-28 1999-09-21 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US6710066B2 (en) * 1989-07-28 2004-03-23 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US20020058008A1 (en) * 1989-07-28 2002-05-16 Kennedy James C. Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US5587490A (en) * 1990-04-16 1996-12-24 Credit Managers Association Of California Method of inactivation of viral and bacterial blood contaminants
US5798238A (en) * 1990-04-16 1998-08-25 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants with quinolines as photosensitizer
US20040110819A1 (en) * 1991-10-28 2004-06-10 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
EP0947222B1 (en) * 1992-11-20 2006-04-12 The University Of British Columbia Method of activating photosensitive agents
EP0831909B1 (en) * 1995-06-05 2005-01-26 Queen's University at Kingston Use of a protoporphyrin ix precursor in the treatment of dermatophytoses and malaria after photoactivation of said protoporphyrin
US6008211A (en) * 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
WO1997016966A1 (en) * 1995-11-06 1997-05-15 New York Blood Center, Inc. Viral inactivation treatment of red blood cells using phthalocyanines and red light
US5895786A (en) 1996-05-08 1999-04-20 New York Blood Center, Inc. Method for treating viral infections
US6159733A (en) * 1996-06-20 2000-12-12 New York Blood Center, Inc. Method for photoinactivating malignant cells
US5922278A (en) † 1996-11-19 1999-07-13 Baxter International Inc. Method and apparatus for inactivating contaminants in biological fluid
US5742380A (en) * 1996-12-31 1998-04-21 Ronn Avigdor M Plasma assay spectrometer
US6010890A (en) * 1997-04-29 2000-01-04 New York Blood Center, Inc. Method for viral inactivation and compositions for use in same
US6103706A (en) * 1997-04-29 2000-08-15 New York Blood Center, Inc. Methods for treating viral infections
US5856566A (en) * 1997-09-02 1999-01-05 Dusa Pharmaceuticals, Inc. Sterilized 5-aminolevulinic acid
US6159178A (en) 1998-01-23 2000-12-12 Heartport, Inc. Methods and devices for occluding the ascending aorta and maintaining circulation of oxygenated blood in the patient when the patient's heart is arrested
US6096066A (en) * 1998-09-11 2000-08-01 Light Sciences Limited Partnership Conformal patch for administering light therapy to subcutaneous tumors
US6183773B1 (en) 1999-01-04 2001-02-06 The General Hospital Corporation Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
US6454789B1 (en) * 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
CA2356532A1 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
WO2000041725A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Therapeutic compositions for metabolic bone disorders or bone metastases
US6376483B1 (en) 1999-05-27 2002-04-23 Miravant Pharmaceuticals, Inc. Bacteriochlorins and bacteriopurpurins useful as photoselective compounds for photodynamic therapy and a process for their production
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
DE19960705A1 (en) * 1999-12-16 2001-06-21 Laser & Med Tech Gmbh Method and device for producing an autologous immunization vaccine against cancer (tumor vaccine)
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US20020049247A1 (en) * 2000-01-12 2002-04-25 Chen James C. Novel treatment for eye disease
KR100365151B1 (en) * 2000-05-08 2003-02-11 김형락 Novel use of delta-aminolevulinic acid for the prevention and treatment of infection by pathogenic microorganism
DE10034673C1 (en) 2000-07-17 2002-04-25 Medac Klinische Spezialpraep Dermal application system for aminolevulinic acid and its use
EP2269645A3 (en) 2000-08-16 2011-01-12 The General Hospital Corporation doing business as Massachusetts General Hospital Topical aminolevulinic acid-photodynamic therapy for acne vulgaris
EP2248536A3 (en) 2000-12-14 2010-12-08 The General Hospital Corporation doing business as Massachusetts General Hospital Topical Aminolevulinic acid-photodynamic therapy for acne vulgaris
US7498029B2 (en) * 2001-05-01 2009-03-03 The General Hospital Corporation Photoimmunotherapies for cancer using combination therapies
US20030103995A1 (en) * 2001-06-04 2003-06-05 Hamblin Michael R. Detection and therapy of vulnerable plaque with photodynamic compounds
DE10162712A1 (en) * 2001-12-19 2003-07-17 Blutspendienst Der Landesverba Process for inactivating bacteria and leukocytes in blood or blood products
WO2003061696A2 (en) * 2002-01-23 2003-07-31 Light Sciences Corporation Systems and methods for photodynamic therapy
EP1517684B1 (en) 2002-06-27 2009-07-22 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
WO2004005289A2 (en) 2002-07-02 2004-01-15 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US7220778B2 (en) * 2003-04-15 2007-05-22 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US7659301B2 (en) * 2003-04-15 2010-02-09 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US20070020272A1 (en) * 2003-04-30 2007-01-25 Tayyaba Hasan Indirectly linked photosensitizer immunoconjugates, processes for the production thereof and methods of use thereof
WO2004105860A2 (en) * 2003-05-29 2004-12-09 Mitos Pharmaceuticals, Inc. Methods of using nitroxides in conjunction with photosensitizers and sonosensitizers
FR2857264A1 (en) * 2003-07-09 2005-01-14 Maco Pharma Sa METHOD FOR PHOTODYNAMIC INACTIVATION OF PATHOGENS BY MEANS OF ALA
GB0424833D0 (en) 2004-11-10 2004-12-15 Photocure Asa Method
US8585707B2 (en) 2006-06-07 2013-11-19 Gary S. Rogers Continuous low irradiance photodynamic therapy method
US20080164224A1 (en) * 2007-01-04 2008-07-10 Whirlpool Corporation System for connecting mechnically dissimilar consumer electronic devices to an adaptor or a host
EP2164418B1 (en) 2007-06-27 2014-01-08 The General Hospital Corporation Apparatus for optical inhibition of photodynamic therapy
US20090062724A1 (en) * 2007-08-31 2009-03-05 Rixen Chen System and apparatus for sonodynamic therapy
US8835104B2 (en) * 2007-12-20 2014-09-16 Fenwal, Inc. Medium and methods for the storage of platelets
JP2014518547A (en) 2011-04-07 2014-07-31 フェンウォール、インコーポレイテッド Automated method and system for providing platelet concentrates with reduced residual plasma volume and storage medium for such platelet concentrates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4961920A (en) * 1988-12-08 1990-10-09 Luminis Pty, Ltd. Phototherapeutic monovinyl and divinyl ether-linked dimers
US4960408A (en) * 1989-01-10 1990-10-02 Klainer Albert S Treatment methods and vaccines for stimulating an immunological response against retroviruses

Also Published As

Publication number Publication date
IL107035A0 (en) 1993-12-28
GR3036479T3 (en) 2001-11-30
AU4940593A (en) 1994-04-12
US5736563A (en) 1998-04-07
EP0660712A1 (en) 1995-07-05
NO951066D0 (en) 1995-03-20
NO951066L (en) 1995-05-19
AU681088B2 (en) 1997-08-21
NZ255302A (en) 2001-04-27
EP0660712B1 (en) 2001-05-30
SK35295A3 (en) 1996-05-08
ES2160600T3 (en) 2001-11-16
IL107035A (en) 1998-12-27
DE69330277T2 (en) 2002-04-18
HU220251B (en) 2001-11-28
ATE201596T1 (en) 2001-06-15
JPH08501301A (en) 1996-02-13
FI951295A (en) 1995-05-17
PT660712E (en) 2001-11-30
TW241204B (en) 1995-02-21
JP3598306B2 (en) 2004-12-08
DE69330277D1 (en) 2001-07-05
PL308116A1 (en) 1995-07-24
WO1994006424A1 (en) 1994-03-31
CA2144327C (en) 2002-08-06
FI951295A0 (en) 1995-03-20
HUT70966A (en) 1995-11-28
DK0660712T3 (en) 2001-08-27
US5484803A (en) 1996-01-16
JP2001316288A (en) 2001-11-13
ZA936968B (en) 1994-04-12

Similar Documents

Publication Publication Date Title
CA2144327A1 (en) Transcutaneous in vivo activation of photosensitive agents in blood
RU93056633A (en) ANTIALLERGIC COMPOSITION FOR TREATMENT OF EYES OR NOSE
CA2109084A1 (en) Biofilm reduction method
AU1934699A (en) Diode laser irradiation and electrotherapy system for biological tissue stimulation
FR2763247B1 (en) ACTIVE IMPLANTABLE MEDICAL DEVICE, IN PARTICULAR A CARDIAC STIMULATOR, DEFIBRILLATOR AND / OR CARDIOVERTER FOR REDUCING ARRHYTHMIA EPISODES, ESPECIALLY ATRIAL ARRHYTHMIA
CA2245766A1 (en) Compositions useful in the phototherapeutic treatment of proliferative skin disorders
CA2254070A1 (en) Method for treating viral infections
DE69623390T2 (en) Active implantable medical device, in particular pacemaker or defibrillator
GR3022015T3 (en) Insecticidal composition
CA2091134A1 (en) Therapeutic agent for threatened abortion
CA2305183A1 (en) Postsurgical treatment with dichloroacetate
NZ213370A (en) Method of treating viral infections of selected trees and field crops using ribavirin (1-b-d-ribofuranosyl-1,2,4-triazole-3-carboxamide) or the 2,3,5-triacetyl or 5'-butyryl derivative thereof
CA2022848A1 (en) Process for disinfecting musculoskeletal tissue and tissues prepared thereby
AU8168294A (en) Solid insecticidal formulation
FI933374A (en) Herbicidal composition, enhancer for improving the effectiveness of herbicide and method for treating crops
FR2779844B1 (en) INTERCONNECTION STRUCTURE BETWEEN ADDRESSABLE ORGANS OF A MICROCALCULATOR, IN PARTICULAR FOR AN IMPLANTABLE ACTIVE MEDICAL DEVICE SUCH AS A CARDIAC STIMULATOR OR DEFIBRILLATOR
IT8920322A0 (en) BIOLOGICAL CONTROL PROCEDURE AGAINST THE CROP DESTROYING INSECT PLUTELLA
RU93025242A (en) METHOD OF LAZEROTHERAPY
IT1280261B1 (en) PROCEDURE FOR THE STERILIZATION AND AERATION OF THE SOIL AND EQUIPMENT TO IMPLEMENT THIS PROCEDURE.
ES1026026Y (en) PERFECTED APERO FOR THE PREPARATION OF LAND FOR PLANTING AND CROPS.
IT8921526A0 (en) PROTECTION FROM ATMOSPHERIC AGENTS, INCLUDING THE FRANDINE, OF VINEYARDS AND OTHER CROPS.
AUPO142296A0 (en) Chemical formulae: for the treatment of termites & borers, also fungus:-above and below ground level
FI960360A0 (en) Herbicidal composition, enhancer for improving the effectiveness of herbicide and method for treating crops
DZ1728A1 (en) Preparation of insecticide against crawling insects.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed